Roche, Bio­gen hand­ing over $470M in cash to bag two drug pro­grams from Bris­tol-My­ers Squibb

Bris­tol-My­ers Squibb has forged a pair of sep­a­rate pacts with Roche and Bio­gen to out­li­cense two drugs, grab­bing a whop­ping $470 mil­lion up­front for the deals.

Bio­gen gets con­trol of BMS-986168, an an­ti-eTau com­pound in clin­i­cal de­vel­op­ment for Pro­gres­sive Supranu­clear Pal­sy, for $300 mil­lion up­front and $410 mil­lion in mile­stones. And Roche gets BMS-986089, an an­ti-myo­statin Ad­nectin in de­vel­op­ment for Duchenne mus­cu­lar dy­s­tro­phy. Roche is pay­ing $170 mil­lion plus $205 mil­lion in mile­stones.

Thomas Lynch, BMS

Bio­gen is al­so as­sum­ing the oblig­a­tions Bris­tol-My­ers took on when it ac­quired iP­ier­ian in 2014 for $175 mil­lion in cash and $550 mil­lion in mile­stones. That deal fo­cused heav­i­ly on the tau pro­gram, along with Bris­tol’s in­ter­est in pur­su­ing it as a com­bo for Alzheimer’s — which odd­ly ar­rived months af­ter Bris­tol’s de­ci­sion to re­treat from neu­ro­sciences work in 2013. But in re­cent years Bris­tol’s in­ter­est in Alzheimer’s has fad­ed, while Bio­gen has been ex­cit­ing the in­dus­try with ear­ly-stage da­ta on ad­u­canum­ab, an amy­loid ther­a­py.

The deals to­tal about $1.1 bil­lion, plus prospec­tive roy­al­ties.

Roche is get­ting its myo­statin drug in Phase I, ac­cord­ing to a spokesper­son at Bris­tol-My­ers.Bris­tol orig­i­nal­ly ac­quired it way back in 2007 with the $505 mil­lion deal to buy Ad­nexus, which orig­i­nal­ly de­vel­oped Ad­nectins.

Bio­gen says it will now launch the Phase II stud­ies for its drug in both Alzheimer’s dis­ease as well as PSP. Notes Baird’s Bri­an Sko­r­ney:

Ad­di­tion of BMS-986168 ex­pands Bio­gen’s port­fo­lio in Alzheimer’s, which al­ready in­cludes an­ti-tau and an­ti-Aβ (ad­u­canum­ab, BAN2401 with Ei­sai) pro­grams and BACE in­hibitor E2609, through a col­lab­o­ra­tion with Ei­sai.

“Bio­gen aims to be a leader in Alzheimer’s dis­ease and we are build­ing a pipeline with mul­ti­ple ap­proach­es to ad­dress the com­plex, dev­as­tat­ing process of neu­rode­gen­er­a­tion,” said Michael Ehlers, ex­ec­u­tive vice pres­i­dent, re­search & de­vel­op­ment. “Based on en­cour­ag­ing safe­ty and ef­fi­ca­cy da­ta, we be­lieve BMS-986168 is a promis­ing an­ti-tau can­di­date that may rep­re­sent the next wave of med­i­cines for Alzheimer’s dis­ease as well as the first re­al an­swer for pro­gres­sive supranu­clear pal­sy.”

Bio­gen has been un­der in­tense pres­sure to add new drugs to its pipeline, which is con­cen­trat­ed on neu­ro­log­i­cal con­di­tions. Roche, though, has been com­ing through with a va­ri­ety of ma­jor league ap­provals, in­clud­ing the re­cent OK for Ocre­vus, and has been choosy about what it wants to add to the pipeline.

Bris­tol-My­ers, mean­while, has been shak­ing up its R&D group in re­cent months, af­ter the fi­as­co with the check­point Op­di­vo as it slipped be­hind Mer­ck’s Keytru­da on non-small cell lung can­cer. Bris­tol-My­ers brought in a new R&D chief, Thomas Lynch, and has been se­lec­tive­ly look­ing for ways to econ­o­mize as it looks to make a come­back in a field that it helped to pi­o­neer.

“Li­cens­ing these as­sets to Bio­gen and Roche will en­able Bris­tol-My­ers Squibb to pri­or­i­tize the oth­er promis­ing op­por­tu­ni­ties for as­set de­vel­op­ment that have ad­vanced across our di­ver­si­fied port­fo­lio,” said Mike Burgess, head of Car­dio­vas­cu­lar, Fi­bro­sis and Im­muno­science De­vel­op­ment, Bris­tol-My­ers Squibb. “We rec­og­nize the sig­nif­i­cant un­met med­ical needs for pa­tients with PSP and with DMD, and are pleased to put the fu­ture de­vel­op­ment of these com­pounds in­to the hands of Bio­gen and Roche, who both have strong ca­pa­bil­i­ties, fo­cus and lead­er­ship in neu­rode­gen­er­a­tive and rare dis­eases.”

Alice Shaw, Lung Cancer Foundation of America

Top ALK ex­pert and can­cer drug re­searcher Al­ice Shaw bids adieu to acad­e­mia, hel­lo to No­var­tis

Jay Bradner has recruited a marquee oncology drug researcher into the ranks of the Novartis Institutes for BioMedical Research. Alice Shaw is jumping from prestigious posts intertwined through Mass General, Harvard and Dana-Farber to take the lead of NIBR’s translational clinical oncology group.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Hal Barron, GSK's president of R&D and CSO, speaks to Endpoints News founder and editor John Carroll in London at Endpoints' #UKBIO19 summit on October 8, 2019

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron talks about a new era at GSK

Last week I had a chance to sit down with Hal Barron at Endpoints’ #UKBIO19 summit to discuss his views on R&D at GSK, a topic that has been central to his life since he took the top research post close to 2 years ago. During the conversation, Barron talked about changing the culture at GSK, a move that involves several new approaches — one of which involves celebrating their setbacks as they shift resources to the most promising programs in the pipeline. Barron also discussed his new alliances in the Bay Area — including his collaboration pact with Lyell, which we covered here — frankly assesses the pluses and minuses of the UK drug development scene, and talks about his plans for making GSK a much more effective drug developer.

This is one discussion you won’t want to miss. Insider and Enterprise subscribers can log-in to watch the video.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Medical animation has in recent years become an increasingly important tool for conveying niche information to a varied audience, particularly to those audiences without expertise in the specialist area. Science programmes today, for example, have moved from the piece-to-camera of the university professor explaining how a complex disease mechanism works, to actually showing the viewer first-hand what it might look like to shrink ourselves down to the size of an ant’s foot, and travel inside the human body to witness these processes in action. Effectively communicating a complex disease pathophysiology, or the novel mechanism of action of a new drug, can be complex. This is especially difficult when the audience domain knowledge is limited or non-existent. Medical animation can help with this communication challenge in several ways.
Improved accessibility to visualisation
Visualisation is a core component of our ability to understand a concept. Ask 10 people to visualise an apple, and each will come up with a slightly different image, some apples smaller than others, some more round, some with bites taken. Acceptable, you say, we can move on to the next part of the story. Now ask 10 people to visualise how HIV’s capsid protein gets arranged into the hexamers and pentamers that form the viral capsid that holds HIV’s genetic material. This request may pose a challenge even to someone with some virology knowledge, and it is that inability to effectively visualise what is going on that holds us back from fully understanding the rest of the story. So how does medical animation help us to overcome this visualisation challenge?

Flu Virus (Source: CDC)

FDA ex­pands Xofluza ap­proval as Roche strug­gles to catch loom­ing flu mar­ket

As a potentially powerful flu season looms, so does a big test for Roche and its new flu drug, Xofluza. The Swiss giant just got a small boost in advance of that test as the FDA expanded Xofluza’s indication to include patients at high risk of developing flu-related complications.

Xofluza (baloxavir marboxil) was approved last October in the US, the first landmark flu drug approval in 20 years and a much-needed green light for a company that had watched its leading flu drug Tamiflu get eaten alive by generics. Like its predecessor, the pill offered a reduction in flu symptoms but not a cure.

EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

The first-ever Ebola vaccine is on the precipice of approval after the European Medicine’s Agency (EMA) backed the Merck product in this week’s roster of recommendations.

The drugmaker $MRK began developing the vaccine, christened Ervebo, during the West African outbreak that occurred between 2014 and 2016, killing more than 11,000.

The current outbreak in the Democratic Republic of Congo (DRC) has shown case fatality rates of approximately 67%, the agency estimated. Earlier this year, the WHO declared the outbreak — which so far has infected more than 3,000 people — a public health emergency of international concern.

Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

→ The outflow of top execs from MedImmune continues to fill the leadership ranks of smaller biotechs. The latest to take off is Ronald Herbst, the head of oncology research, who’s assuming the CSO post at Pyxis Oncology.  

Herbst was part of the old MedImmune organization AstraZeneca CEO Pascal Soriot restructured earlier this year, reorganizing the company and eliminating the storied subsidiary as a separate organization.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Mi­rati preps its first look at their KRAS G12C con­tender, and they have to clear a high bar for suc­cess

If you’re a big KRAS G12C fan, mark your calendars for October 28 at 4:20 pm EDT.

That’s when Mirati $MRTX will unveil its first peek at the early clinical data available on MRTX849 in presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Mirati has been experiencing the full effect of a rival’s initial success at targeting the G12C pocket found on KRAS, offering the biotech some support on the concept they’re after — and biotech fans a race to the top. Amgen made a big splash with its first positive snapshot on lung cancer, but deflated sky-high expectations as it proved harder to find similar benefits in other types of cancers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

The FDA will hus­tle up an ex­pe­dit­ed re­view for As­traZeneca’s next shot at a block­buster can­cer drug fran­chise

AstraZeneca paid a hefty price to partner with Daiichi Sankyo on their experimental antibody drug conjugate for HER2 positive breast cancer. And they’ve been rewarded with a fast ride through the FDA, with a straight shot at creating another blockbuster oncology franchise.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.

Sean Parker, AP

Sean Park­er helps cre­ate a CRISPRed cell ther­a­py 2.0 play — and he’s got a high-pro­file set of lead­ers on the team

You can rack up one more high-profile debut effort in the wave of activity forming around cell therapy 2.0. It’s another appealing Bay Area group that’s attracted some of the top hands in the business to a multi-year effort to create a breakthrough. And they have $85 million in hand to make that first big step to the clinic.

Today it’s Ken Drazan and the team at South San Francisco-based ArsenalBio that are coming from behind the curtain for a public bow, backed by billionaire Sean Parker and a collection of investors that includes Beth Seidenberg’s new venture investment operation based in LA.
Drazan — a J&J Innovation vet with a long record of entrepreneurial endeavors — exited the stage in 2018 when his last mission ended as he stepped aside as president of Grail. It wasn’t long, though, before he was helping out with a business plan for ArsenalBio that revolved around the work of a large group of interconnected scientists supported by the Parker Institute for Cancer Immunology.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.